BioCentury
ARTICLE | Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

April 29, 2020 11:56 PM UTC

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data against one of the newer immuno-oncology targets. New targets and data for a bispecific mAb showed early promise at the meeting earlier this week.

In the biggest miss for Roche (SIX:ROG; OTCQX:RHHBY), data from the Phase III IMbassador250 trial showed Tecentriq plus Xtandi enzalutamide missed the primary endpoint of overall survival (OS) vs. Xtandi alone in 759 patients with metastatic castration-resistant prostate cancer (CRPC). The combination had a median OS of 15.2 months vs. 16.6 months for Xtandi alone (HR=1.12; p=0.28)...